nach oben

Erschienen in:

16.04.2023 | Special Section: PET/MR

PET/MRI in colorectal and anal cancers: an update

verfasst von: Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum

Erschienen in: Abdominal Radiology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Positron emission tomography (PET) in the era of personalized medicine has a unique role in the management of oncological patients and offers several advantages over standard anatomical imaging. However, the role of molecular imaging in lower GI malignancies has historically been limited due to suboptimal anatomical evaluation on the accompanying CT, as well as significant physiological ¹⁸F-flurodeoxyglucose (FDG) uptake in the bowel. In the last decade, technological advancements have made whole-body FDG-PET/MRI a feasible alternative to PET/CT and MRI for lower GI malignancies. PET/MRI combines the advantages of molecular imaging with excellent soft tissue contrast resolution. Hence, it constitutes a unique opportunity to improve the imaging of these cancers. FDG-PET/MRI has a potential role in initial diagnosis, assessment of local treatment response, and evaluation for metastatic disease. In this article, we review the recent literature on FDG-PET/MRI for colorectal and anal cancers; provide an example whole-body FDG-PET/MRI protocol; highlight potential interpretive pitfalls; and provide recommendations on particular clinical scenarios in which FDG-PET/MRI is likely to be most beneficial for these cancer types.

Graphical abstract

Cancer Stat Facts: Colorectal Cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed on November 16th, 2022

Cancer Stat Facts: Anal Cancer. https://seer.cancer.gov/statfacts/html/anus.html. Accessed on November 16th, 2022

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.PubMedCrossRef

Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-76.PubMedPubMedCentralCrossRef

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(7):852-71.PubMedPubMedCentralCrossRef

Filippiadis DK, Velonakis G, Kelekis A, Sofocleous CT. The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease. Diagnostics (Basel). 2021;11(2).

Jayaprakasam VS, Paroder V, Schöder H. Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. Semin Nucl Med. 2021;51(5):485-501.PubMedPubMedCentralCrossRef

Tahtabasi M, Erturk SM, Basak M. Comparison of MRI and 18F-FDG PET/CT in the Liver Metastases of Gastrointestinal and Pancreaticobiliary Tumors. Sisli Etfal Hastan Tip Bul. 2021;55(1):12-7.PubMedPubMedCentral

Mercury Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779.PubMedCentralCrossRef

10.

Mercury Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132-9.CrossRef

11.

Bugg WG, Andreou AK, Biswas D, Toms AP, Williams SM. The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma. Clin Radiol. 2014;69(6):619-23.PubMedCrossRef

12.

Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32(9):1087-100.PubMedCrossRef

13.

Prezzi D, Mandegaran R, Gourtsoyianni S, Owczarczyk K, Gaya A, Glynne-Jones R, et al. The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. Eur Radiol. 2018;28(4):1512-9.PubMedCrossRef

14.

Kochhar R, Renehan AG, Mullan D, Chakrabarty B, Saunders MP, Carrington BM. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol. 2017;27(2):607-17.PubMedCrossRef

15.

Overcast WB, Davis KM, Ho CY, Hutchins GD, Green MA, Graner BD, et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021;23(3):34.PubMedPubMedCentralCrossRef

16.

Berzaczy D, Fueger B, Hoeller C, Haug AR, Staudenherz A, Berzaczy G, et al. Whole-Body [(18)F]FDG-PET/MRI vs. [(18)F]FDG-PET/CT in Malignant Melanoma. Mol Imaging Biol. 2020;22(3):739-44.PubMedCrossRef

17.

Mulé S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, et al. Whole-Body Functional MRI and PET/MRI in Multiple Myeloma. Cancers (Basel). 2020;12(11).CrossRef

18.

Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Schöder H. MRI and PET/MRI in hematologic malignancies. J Magn Reson Imaging. 2020;51(5):1325-35.PubMedCrossRef

19.

Paspulati RM, Partovi S, Herrmann KA, Krishnamurthi S, Delaney CP, Nguyen NC. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study. Abdom Imaging. 2015;40(6):1415-25.PubMedCrossRef

20.

Furtado FS, Suarez-Weiss KE, Vangel M, Clark JW, Cusack JC, Hong T, et al. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021;125(7):975-82.PubMedPubMedCentralCrossRef

21.

Yasuda S, Takechi M, Ono M, Miyatake Y, Itoh M, Kojima T, et al. The effect of glucagon on FDG uptake in skeletal muscle. Tokai J Exp Clin Med. 2012;37(1):11-3.PubMed

22.

Fraum TJ, Ma J, Jhaveri K, Nepal P, Lall C, Costello J, et al. The optimized rectal cancer MRI protocol: choosing the right sequences, sequence parameters, and preparatory strategies. Abdom Radiol (NY). 2023.

23.

Jayaprakasam VS, Javed-Tayyab S, Gangai N, Zheng J, Capanu M, Bates DDB, et al. Does microenema administration improve the quality of DWI sequences in rectal MRI? Abdom Radiol (NY). 2021;46(3):858-66.PubMedCrossRef

24.

Plodeck V, Rahbari NN, Weitz J, Radosa CG, Laniado M, Hoffmann R-T, et al. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences. European Radiology. 2019;29(1):422-8.PubMedCrossRef

25.

Kang B, Lee JM, Song YS, Woo S, Hur BY, Jeon JH, et al. Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT. AJR Am J Roentgenol. 2016;206(1):W10-20.PubMedCrossRef

26.

Seto S, Tsujikawa T, Sawai K, Kurebayashi H, Morikawa M, Okazawa H, et al. Feasibility of [18F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer. Oncology. 2022;100(4):212-20.PubMedCrossRef

27.

Rectal Cancer PET/MRI Staging Protocol for Siemens mMR & GE SIGNA. Society of Abdominal Radiology Rectal and Anal Cancer Disease-Focussed Panel. https://abdominalradiology.org/wp-content/uploads/2021/01/PMR-Rectal-Cancer-Protocols-Siemens-GE-v3.pdf. Accessed Novemebr 20th, 2022.

28.

Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, et al. Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017;7(1):77.PubMedPubMedCentralCrossRef

29.

Rutegård MK, Båtsman M, Axelsson J, Brynolfsson P, Brännström F, Rutegård J, et al. PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study. Cancer Imaging. 2019;19(1):52.PubMedPubMedCentralCrossRef

30.

Bailey JJ, Jordan EJ, Burke C, Ohliger MA, Wang ZJ, Van Loon K, et al. Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results? AJR Am J Roentgenol. 2018;211(4):896-900.PubMedPubMedCentralCrossRef

31.

Maffione AM, Chondrogiannis S, Capirci C, Galeotti F, Fornasiero A, Crepaldi G, et al. Early prediction of response by (1)(8)F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014;40(10):1186-94.PubMedCrossRef

32.

Bang JI, Ha S, Kang SB, Lee KW, Lee HS, Kim JS, et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2016;43(3):422-31.PubMedCrossRef

33.

Wiesmüller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging. 2013;40(1):12-21.PubMedCrossRef

34.

Jeong JH, Cho IH, Chun KA, Kong EJ, Kwon SD, Kim JH. Correlation Between Apparent Diffusion Coefficients and Standardized Uptake Values in Hybrid (18)F-FDG PET/MR: Preliminary Results in Rectal Cancer. Nucl Med Mol Imaging. 2016;50(2):150-6.PubMedPubMedCentralCrossRef

35.

Bailey DL, Barthel H, Beyer T, Boellaard R, Gückel B, Hellwig D, et al. Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol. 2013;15(4):361-71.PubMedCrossRef

36.

Afaq A, Faul D, Chebrolu VV, Wan S, Hope TA, Haibach PV, et al. Pitfalls on PET/MRI. Seminars in Nuclear Medicine. 2021;51(5):529-39.PubMedCrossRef

37.

Leynes AP, Yang J, Wiesinger F, Kaushik SS, Shanbhag DD, Seo Y, et al. Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI. J Nucl Med. 2018;59(5):852-8.PubMedPubMedCentralCrossRef

38.

Jang H, Liu F, Bradshaw T, McMillan AB. Rapid dual-echo ramped hybrid encoding MR-based attenuation correction (dRHE-MRAC) for PET/MR. Magn Reson Med. 2018;79(6):2912-22.PubMedCrossRef

39.

Oehmigen M, Lindemann ME, Gratz M, Kirchner J, Ruhlmann V, Umutlu L, et al. Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR. Eur J Nucl Med Mol Imaging. 2018;45(4):642-53.PubMedCrossRef

40.

Er H, Erden A, Küçük N, Geçim E. Correlation of minimum apparent diffusion coefficient with maximum standardized uptake on fluorodeoxyglucose PET-CT in patients with rectal adenocarcinoma. Diagn Interv Radiol. 2014;20(2):105-9.PubMed

41.

Surov A, Meyer HJ, Schob S, Höhn AK, Bremicker K, Exner M, et al. Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer. Oncotarget. 2017;8(17):28285-96.PubMedPubMedCentralCrossRef

42.

Queiroz MA, Naves A, Dreyer PR, Cerri GG, Buchpiguel CA. PET/MRI Characterization of Mucinous Versus Nonmucinous Components of Rectal Adenocarcinoma: A Comparison of Tumor Metabolism and Cellularity. American Journal of Roentgenology. 2020;216(2):376-83.PubMedCrossRef

43.

Catalano OA, Lee SI, Parente C, Cauley C, Furtado FS, Striar R, et al. Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. 2021;48(4):1235-45.PubMedCrossRef

44.

Sakin A, Sahin S, Karyagar SS, Karyagar S, Atci M, Akboru MH, et al. The Predictive Value of Baseline Volumetric PET/CT Parameters on Treatment Response and Prognosis in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. J Gastrointest Cancer. 2022;53(2):341-7.PubMedCrossRef

45.

Herold A, Wassipaul C, Weber M, Lindenlaub F, Rasul S, Stift A, et al. Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2022;50(1):205-17.PubMedPubMedCentralCrossRef

46.

Queiroz MA, Ortega CD, Ferreira FR, Capareli FC, Nahas SC, Cerri GG, et al. Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease. Mol Imaging Biol. 2022;24(3):453-63.PubMedCrossRef

47.

Lee SJ, Seo HJ, Kang KW, Jeong SY, Yi NJ, Lee JM, et al. Clinical Performance of Whole-Body 18F-FDG PET/Dixon-VIBE, T1-Weighted, and T2-Weighted MRI Protocol in Colorectal Cancer. Clin Nucl Med. 2015;40(8):e392-8.PubMedCrossRef

48.

Mirshahvalad SA, Hinzpeter R, Kohan A, Anconina R, Kulanthaivelu R, Ortega C, et al. Diagnostic performance of [(18)F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022;49(12):4205-17.PubMedCrossRef

49.

Maas M, Lambregts DMJ, Lahaye MJ, Beets GL, Backes W, Vliegen RFA, et al. T-staging of rectal cancer: accuracy of 3.0 Tesla MRI compared with 1.5 Tesla. Abdominal Imaging. 2012;37(3):475-81.PubMedCrossRef

50.

Dos Anjos DA, Habr-Gama A, Vailati BB, Rossi CB, Coturel AE, Perez RO, et al. (18)F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes. Ann Nucl Med. 2016;30(8):513-7.PubMedCrossRef

51.

Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg. 2003;90(3):355-64.PubMedCrossRef

52.

van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology. 2013;269(1):101-12.PubMedCrossRef

53.

Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2017.

54.

Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol. 2008;38(5):347-53.PubMedCrossRef

55.

Kim DJ, Kim JH, Ryu YH, Jeon TJ, Yu JS, Chung JJ. Nodal staging of rectal cancer: high-resolution pelvic MRI versus 18F-FDGPET/CT. J Comput Assist Tomogr. 2011;35(5):531-4.PubMedCrossRef

56.

Catalano OA, Coutinho AM, Sahani DV, Vangel MG, Gee MS, Hahn PF, et al. Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol (NY). 2017;42(4):1141-51.PubMedCrossRef

57.

Hope TA, Kassam Z, Loening A, McNamara MM, Paspulati R. The use of PET/MRI for imaging rectal cancer. Abdom Radiol (NY). 2019;44(11):3559-68.PubMedPubMedCentralCrossRef

58.

Queiroz MA, Ortega CD, Ferreira FR, Nahas SC, Cerri GG, Buchpiguel CA. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(1):186-95.PubMedCrossRef

59.

Li Y, Mueller LI, Neuhaus JP, Bertram S, Schaarschmidt BM, Demircioglu A, et al. (18)F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? J Clin Med. 2020;9(10).

60.

Yoon JH, Lee JM, Chang W, Kang HJ, Bandos A, Lim HJ, et al. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT. Radiology. 2020;294(2):310-9.PubMedCrossRef

61.

Zhou N, Guo X, Sun H, Yu B, Zhu H, Li N, et al. The Value of (18)F-FDG PET/CT and Abdominal PET/MRI as a One-Stop Protocol in Patients With Potentially Resectable Colorectal Liver Metastases. Front Oncol. 2021;11:714948.PubMedPubMedCentralCrossRef

62.

Lee DH, Lee JM, Hur BY, Joo I, Yi NJ, Suh KS, et al. Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging. Radiology. 2016;280(3):782-92.PubMedCrossRef

63.

Brendle C, Schwenzer NF, Rempp H, Schmidt H, Pfannenberg C, la Fougère C, et al. Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging. 2016;43(1):123-32.PubMedCrossRef

64.

Crimì F, Spolverato G, Lacognata C, Garieri M, Cecchin D, Urso ED, et al. 18F-FDG PET/MRI for Rectal Cancer TNM Restaging After Preoperative Chemoradiotherapy: Initial Experience. Dis Colon Rectum. 2020;63(3):310-8.PubMedCrossRef

65.

Amorim BJ, Hong TS, Blaszkowsky LS, Ferrone CR, Berger DL, Bordeianou LG, et al. Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2019;46(11):2260-9.PubMedCrossRef

66.

Ince S, Itani M, Henke LE, Smith RK, Wise PE, Mutch MG, et al. FDG-PET/MRI for Nonoperative Management of Rectal Cancer: A Prospective Pilot Study. Tomography. 2022;8(6):2723-34.PubMedPubMedCentralCrossRef

67.

Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clin Cancer Res. 2020;26(13):3271-9.PubMedPubMedCentralCrossRef

68.

André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-18.PubMedCrossRef

69.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-9.PubMedCrossRef

70.

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-33.PubMedCrossRef

71.

Plodeck V, Platzek I, Streitzig J, Nebelung H, Blum S, Kühn JP, et al. Diagnostic performance of (18)F-fluorodeoxyglucose-PET/MRI versus MRI alone in the diagnosis of pelvic recurrence of rectal cancer. Abdom Radiol (NY). 2021;46(11):5086-94.PubMedPubMedCentralCrossRef

72.

Manafi-Farid R, Kupferthaler A, Wundsam H, Gruber G, Vali R, Venhoda C, et al. Additional Value of 2-[(18)F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients. J Clin Med. 2020;9(9).

73.

Adusumilli P, Elsayed N, Theophanous S, Samuel R, Cooper R, Casanova N, et al. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy. Eur Radiol. 2022;32(8):5086-96.PubMedPubMedCentralCrossRef

74.

Schramm G, Maus J, Hofheinz F, Petr J, Lougovski A, Beuthien-Baumann B, et al. Evaluation and automatic correction of metal-implant-induced artifacts in MR-based attenuation correction in whole-body PET/MR imaging. Phys Med Biol. 2014;59(11):2713-26.PubMedCrossRef

75.

Schramm G, Langner J, Hofheinz F, Petr J, Lougovski A, Beuthien-Baumann B, et al. Influence and compensation of truncation artifacts in MR-based attenuation correction in PET/MR. IEEE Trans Med Imaging. 2013;32(11):2056-63.PubMedCrossRef

76.

Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.PubMedPubMedCentralCrossRef

77.

Ihn MH, Kim DW, Cho S, Oh HK, Jheon S, Kim K, et al. Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors. Cancer Res Treat. 2017;49(1):104-15.PubMedCrossRef

78.

Chandarana H, Heacock L, Rakheja R, DeMello LR, Bonavita J, Block TK, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology. 2013;268(3):874-81.PubMedCrossRef

79.

Burris NS, Johnson KM, Larson PE, Hope MD, Nagle SK, Behr SC, et al. Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System. Radiology. 2016;278(1):239-46.PubMedCrossRef

80.

Torrado-Carvajal A, Vera-Olmos J, Izquierdo-Garcia D, Catalano OA, Morales MA, Margolin J, et al. Dixon-VIBE Deep Learning (DIVIDE) Pseudo-CT Synthesis for Pelvis PET/MR Attenuation Correction. J Nucl Med. 2019;60(3):429-35.PubMedPubMedCentralCrossRef

81.

Dong X, Wang T, Lei Y, Higgins K, Liu T, Curran WJ, et al. Synthetic CT generation from non-attenuation corrected PET images for whole-body PET imaging. Phys Med Biol. 2019;64(21):215016.PubMedPubMedCentralCrossRef

82.

Ganeshan B, Miles K, Afaq A, Punwani S, Rodriguez M, Wan S, et al. Texture Analysis of Fractional Water Content Images Acquired during PET/MRI: Initial Evidence for an Association with Total Lesion Glycolysis, Survival and Gene Mutation Profile in Primary Colorectal Cancer. Cancers (Basel). 2021;13(11).

83.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-5.PubMedPubMedCentralCrossRef

84.

Kömek H, Can C, Kaplan İ, Gündoğan C, Kepenek F, Karaoglan H, et al. Comparison of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT and [(18)F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022;49(11):3898-909.PubMedCrossRef

85.

Huang D, Wu J, Zhong H, Li Y, Han Y, He Y, et al. [(68)Ga]Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022.

Titel: PET/MRI in colorectal and anal cancers: an update
verfasst von: Vetri Sudar Jayaprakasam
Semra Ince
Garima Suman
Pankaj Nepal
Thomas A. Hope
Raj Mohan Paspulati
Tyler J. Fraum
Publikationsdatum: 16.04.2023
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 12/2023
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-023-03897-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

PET/MRI in colorectal and anal cancers: an update

Abstract

Graphical abstract

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Differentiation between renal epithelioid angiomyolipoma and clear cell renal cell carcinoma using clear cell likelihood score

Potential applications of PET/MRI in non-oncologic conditions within the abdomen and pelvis

Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma

Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies

Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI

Letter to the editor on “Segmentation methods applied to MRI-derived radiomic analysis for the prediction of placenta accreta spectrum in patients with placenta previa”

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie